The Department of Health has provided 4 medicines to combat the Corona virus.
Abu Dhabi is the first city in the world to receive the drug “EvoShield” to treat “Covid-19”
The first shipment of "Evoshield" arrived yesterday in Abu Dhabi, under the supervision of the Abu Dhabi Health Authority.
From the source
The first shipments of the drug "EvoShield", which was developed by the company "AstraZeneca", arrived in the UAE, thus becoming Abu Dhabi, the first city in the world to receive the drug, after obtaining emergency use approval by the Ministry of Health and Community Protection, as the development of the drug that works by generating antibodies came to the Emirates. Long-acting, for the treatment of severe infections in patients who do not show an adequate immune response to fight the virus.
The new drug is added to the other therapeutic and preventive drugs for “Covid-19” available in Abu Dhabi and the UAE, which aim to continue providing the best health care services to all members of society according to the highest international standards, as the Abu Dhabi Health Department previously provided the three latest drugs in the world to treat “Corona” These are kazerifimab and imdivimab, and AstraZeneca AZD7442, in addition to sotrovimab.
The first shipment of "EvoShield" drug arrived in Abu Dhabi yesterday, under the direct supervision of the Abu Dhabi Department of Health, and through close cooperation and joint coordination between a group of major partners, including the "Rafid" company, which specializes in the procurement of equipment and services related to the health care sector. Etihad Cargo, a subsidiary of Etihad Airways, the British-Swedish multinational AstraZeneca, and Abu Dhabi Airports Company.
The innovative drug was stored in Rafid's distribution center, the largest and most advanced low-temperature storage facility in the region, and then distributed to various destinations.
Abu Dhabi continues to provide a pioneering model in responding to the “Covid-19” pandemic, leading the world’s leading cities in dealing with the epidemic, according to the latest classification issued by the London-based Deep Knowledge Group, which confirms the emirate’s position as a leading destination for health care in the world. region and the world.
The Abu Dhabi Department of Health, as part of its continuous efforts to ensure the health and safety of all members of society, has provided the drug "Roche" (cazerifimab and imdivimab), which works to prevent corona virus and treat patients with mild and moderate conditions in the emirate, as it consists of a mixture of antibodies It consists of the drugs "cazerifimab" and "imdivimab", which are able to treat people infected with the virus and prevent disease.
The department also provided the drug “AstraZeneca AZD7442”, so that the UAE, after obtaining the necessary use approvals, is among the first countries to use this drug that generates antibodies for patients with weak immunity, noting that “AZD7442” is the first long-acting drug, which is It is based on antibodies, which has been proven through clinical trials in the third phase to provide prevention and treatment against “Covid-19” disease, and to protect those who are still at risk despite obtaining the vaccine.
In addition to the two drugs (Cazerivimab and Emdivimab) and “AstraZeneca AZD7442”, Abu Dhabi was the first city in the world to receive last June a shipment of the drug “Sutrovimab”, which is intended to treat infection with the “Covid-19” virus, becoming the first city in the world to receive the new treatment.
Dr. Jamal Muhammad Al Kaabi, Undersecretary of the Department of Health in Abu Dhabi, said: “We continue to work under the directives of our leadership to ensure the provision of innovative and promising solutions and treatments to all members of society in Abu Dhabi, where the important partnerships that bring us together with leading global institutions are an integral part of the efforts made to maintain health and safety. Residents of the emirate and those coming to it.
And the company “AstraZeneca” announced last August that the drug “EvoShield” showed a significant decrease in the statistics of the infection rate of the “Covid-19” virus with the symptoms associated with it within the third stage that proved its feasibility in the pre-exposure prevention experiment.
Last October, it also announced a significant decrease in the statistics of the percentage of dangerous “Covid-19” cases or death, compared to the placebo, among non-hospitalized patients and those infected with the “Covid-19” virus with mild to moderate symptoms in the third stage.
• “EvoShield” showed a significant decrease in the statistics of the infection rate of the “Covid-19” virus.
Components of Evoshield
Evoshield is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061), that were developed from the B immune cells of patients recovering from SARS-CoV-2, and the drug was discovered by Vanderbilt University Medical Center. In the United States of America, AstraZeneca obtained its license in 2020.
The mechanism of action of these human monoclonal antibodies is to bind to specific sites of the SARS-CoV-2 spiny protein, blocking its binding to host cells.
And “AstraZeneca” worked to develop the drug by extending its half-life and reducing the binding to the receptor “Fc” and the complement factor “C1q”, as extending the half-life of the drug contributed to an increase in its effect period by three times compared to traditional antibodies, as well as its ability to provide protection. of the “Covid-19” virus for up to 12 months after one use.
Reducing the binding to the receptor “Fc” aims to reduce the phenomenon of exacerbation of the disease dependent on antibodies, which occurs as a result of some antiviral antibodies enhancing the effect of the disease rather than reducing it.
Evoshield is subject to a comprehensive clinical trial program to study its effect in preventing and treating “Covid-19” disease in more than 9,000 people.
Follow our latest local and sports news and the latest political and economic developments via Google news